Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

NCT00544167 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Paclitaxel
DRUG: Sorafenib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]